An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion criteria

Over 65
Renal or liver disease
Diabetes
Hypertension
Taking thiazides or ACE inhibitors

Treatment and study plan

Allopurinal

Drug

300mg once daily by mouth for four weeks

Primary outcomes

Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia

Time frame: baseline and 4 weeks

Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)

Secondary outcomes

Simpson Angus Scale for Parkinsonism

Time frame: baseline and 4 weeks

Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)

Sponsors and collaborators

Lead sponsor

Bronx Psychiatric Center

Other Gov

Registry information

Important dates

Study start: 2005
Primary completion: 2008
Study completion: 2008
First posted: Jan 15, 2009
Registry last updated: Aug 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed